Gyre Therapeutics (GYRE) vs Pharming Group N.V. (PHAR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Gyre Therapeutics (GYRE) has outperformed Pharming Group N.V. (PHAR) over the past year, losing 3.2% versus a loss of 34.2%. Over five years, PHAR leads with a +2.2% price change compared with -88.3% for GYRE. Gyre Therapeutics is the larger company by market cap ($716.8 million vs $674.5 million), about 1.1 times the size.
On valuation, Pharming Group N.V. trades at a lower forward P/E (31.0x vs 112.7x for Gyre Therapeutics).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GYRE | PHAR |
|---|---|---|
| Share price | $6.76 | $9.53 |
| Market cap | $716.79M | $674.52M |
| 1-day change | -3.98% | -1.24% |
| YTD return | -0.28% | -45.39% |
| 1-year return | -3.16% | -34.22% |
| 5-year return | -88.27% | +2.22% |
| P/E ratio (TTM) | — | 73.31 |
| Forward P/E | 112.67 | 31.04 |
| EPS (TTM) | $-0.25 | $0.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.42 | $21.34 |
| 52-week low | $5.44 | $9.44 |
| Distance from 52-week high | -28.24% | -55.34% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +176.18% | +260.44% |
| Average volume | 105.59K | 22.82K |
| Shares outstanding | 106.03M | 70.78M |
| Employees | 625 | 407 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GYRE has outperformed PHAR by 31.1 percentage points over the past year.
About Gyre Therapeutics
GYRE stock →Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees
About Pharming Group N.V.
PHAR stock →Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 407 employees
GYRE vs PHAR FAQ
Which is bigger, Gyre Therapeutics or Pharming Group N.V.?
Gyre Therapeutics (GYRE) is larger, with a market capitalization of $716.79M compared with $674.52M for Pharming Group N.V. (PHAR).
Which stock has performed better over the past year, GYRE or PHAR?
GYRE returned -3.16% over the past 12 months, compared with -34.22% for PHAR (price return, excluding dividends). Past performance does not predict future results.
Are Gyre Therapeutics and Pharming Group N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.